TransCode Therapeutics
RNAZ
12 hedge funds and large institutions have $263K invested in TransCode Therapeutics in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
200% more funds holding
Funds holding: 4 → 12 (+8)
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
7% less capital invested
Capital invested by funds: $284K → $263K (-$21.1K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$72.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$37.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$24.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.1K |
| 5 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
+$19.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$229K |
| 2 |
VF
Virtu Financial
New York
|
-$35.6K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$8.9K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$3 |
RNAZ Hedge Fund Activity: Q2 2024 in Review
12 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q2 2024, worth a combined $263K — down 7.4% from $284K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new RNAZ positions and 1 closed out — a net gain of 8 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $72.1K. The largest seller was Sabby Management, exiting entirely with an estimated $229K sold.
- 12 institutional investors held TransCode Therapeutics (RNAZ) as of Q2 2024, up from 4 in Q1 2024.
- Funds reported $263K of TransCode Therapeutics stock for Q2 2024, down 7.4% quarter-over-quarter.
- 9 funds opened new TransCode Therapeutics positions in Q2 2024 and 1 closed out, a net change of +8 holders.
- The largest TransCode Therapeutics buyer in Q2 2024 was UBS Group, an estimated $72.1K added.
- The largest TransCode Therapeutics seller in Q2 2024 was Sabby Management, an estimated $229K sold.
Based on aggregated 13F filings for Q2 2024.